Regulation  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
sodium  ||| S:14 E:21 ||| JJ
transporters  ||| S:21 E:34 ||| NN
in  ||| S:34 E:37 ||| IN
the  ||| S:37 E:41 ||| DT
kidney  ||| S:41 E:48 ||| NN
during  ||| S:48 E:55 ||| IN
cyclosporine  ||| S:55 E:68 ||| JJ
treatment  ||| S:68 E:78 ||| NN
Cyclosporine  ||| S:78 E:91 ||| NNP
( ||| S:91 E:92 ||| -LRB-
CsA ||| S:92 E:95 ||| NNP
)  ||| S:95 E:97 ||| -RRB-
is  ||| S:97 E:100 ||| VBZ
among  ||| S:100 E:106 ||| IN
the  ||| S:106 E:110 ||| DT
most  ||| S:110 E:115 ||| RBS
widely  ||| S:115 E:122 ||| RB
used  ||| S:122 E:127 ||| VBN
immunosuppressants  ||| S:127 E:146 ||| VBN
for  ||| S:146 E:150 ||| IN
preventing  ||| S:150 E:161 ||| VBG
graft  ||| S:161 E:167 ||| JJ
rejection  ||| S:167 E:177 ||| NN
and  ||| S:177 E:181 ||| CC
autoimmune  ||| S:181 E:192 ||| JJ
diseases ||| S:192 E:200 ||| NNS
.  ||| S:200 E:202 ||| .
However ||| S:202 E:209 ||| RB
,  ||| S:209 E:211 ||| ,
its  ||| S:211 E:215 ||| PRP$
clinical  ||| S:215 E:224 ||| JJ
use  ||| S:224 E:228 ||| NN
is  ||| S:228 E:231 ||| VBZ
hampered  ||| S:231 E:240 ||| VBN
by  ||| S:240 E:243 ||| IN
its  ||| S:243 E:247 ||| PRP$
significant  ||| S:247 E:259 ||| JJ
nephrotoxicity  ||| S:259 E:274 ||| NN
and  ||| S:274 E:278 ||| CC
effects  ||| S:278 E:286 ||| NNS
as  ||| S:286 E:289 ||| IN
a  ||| S:289 E:291 ||| DT
cause  ||| S:291 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
hypertension ||| S:300 E:312 ||| NN
.  ||| S:312 E:314 ||| .
The  ||| S:314 E:318 ||| DT
proximal  ||| S:318 E:327 ||| FW
tubular  ||| S:327 E:335 ||| FW
Na+-H+  ||| S:335 E:342 ||| FW
exchanger  ||| S:342 E:352 ||| FW
( ||| S:352 E:353 ||| -LRB-
NHE3 ||| S:353 E:357 ||| NNP
)  ||| S:357 E:359 ||| -RRB-
is  ||| S:359 E:362 ||| VBZ
responsible  ||| S:362 E:374 ||| JJ
for  ||| S:374 E:378 ||| IN
transcellular  ||| S:378 E:392 ||| JJ
reabsorption  ||| S:392 E:405 ||| NN
of  ||| S:405 E:408 ||| IN
30 ||| S:408 E:410 ||| CD
% ||| S:410 E:411 ||| NN
-60 ||| S:411 E:414 ||| CD
%  ||| S:414 E:416 ||| NN
of  ||| S:416 E:419 ||| IN
the  ||| S:419 E:423 ||| DT
sodium  ||| S:423 E:430 ||| JJ
filtered  ||| S:430 E:439 ||| NN
by  ||| S:439 E:442 ||| IN
the  ||| S:442 E:446 ||| DT
glomerulus ||| S:446 E:456 ||| NN
.  ||| S:456 E:458 ||| .
CsA  ||| S:458 E:462 ||| NNP
induces  ||| S:462 E:470 ||| VBZ
a  ||| S:470 E:472 ||| DT
reduction  ||| S:472 E:482 ||| NN
of  ||| S:482 E:485 ||| IN
absolute  ||| S:485 E:494 ||| JJ
sodium  ||| S:494 E:501 ||| JJ
reabsorption ||| S:501 E:513 ||| NN
,  ||| S:513 E:515 ||| ,
and  ||| S:515 E:519 ||| CC
this  ||| S:519 E:524 ||| DT
effect  ||| S:524 E:531 ||| NN
is ||| S:531 E:533 ||| VBZ
,  ||| S:533 E:535 ||| ,
most  ||| S:535 E:540 ||| RBS
probably ||| S:540 E:548 ||| RB
,  ||| S:548 E:550 ||| ,
correlated  ||| S:550 E:561 ||| VBG
with  ||| S:561 E:566 ||| IN
the  ||| S:566 E:570 ||| DT
decrease  ||| S:570 E:579 ||| NN
of  ||| S:579 E:582 ||| IN
NHE3  ||| S:582 E:587 ||| CD
activity ||| S:587 E:595 ||| NN
.  ||| S:595 E:597 ||| .
In  ||| S:597 E:600 ||| IN
Henle ||| S:600 E:605 ||| NNP
's  ||| S:605 E:608 ||| POS
loop ||| S:608 E:612 ||| NN
,  ||| S:612 E:614 ||| ,
in  ||| S:614 E:617 ||| IN
physiological  ||| S:617 E:631 ||| JJ
conditions ||| S:631 E:641 ||| NNS
,  ||| S:641 E:643 ||| ,
the  ||| S:643 E:647 ||| DT
Na+-K+-2Cl-  ||| S:647 E:659 ||| CD
cotransporter  ||| S:659 E:673 ||| NNS
( ||| S:673 E:674 ||| -LRB-
NKCC2 ||| S:674 E:679 ||| NNP
)  ||| S:679 E:681 ||| -RRB-
reabsorbs  ||| S:681 E:691 ||| VBZ
approximately  ||| S:691 E:705 ||| RB
20 ||| S:705 E:707 ||| CD
%  ||| S:707 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
the  ||| S:712 E:716 ||| DT
filtered  ||| S:716 E:725 ||| JJ
Na+  ||| S:725 E:729 ||| NN
and  ||| S:729 E:733 ||| CC
Cl- ||| S:733 E:736 ||| JJ
.  ||| S:736 E:738 ||| .
CsA  ||| S:738 E:742 ||| JJ
increases  ||| S:742 E:752 ||| NNS
the  ||| S:752 E:756 ||| DT
NKCC2  ||| S:756 E:762 ||| JJ
activity  ||| S:762 E:771 ||| NN
in  ||| S:771 E:774 ||| IN
cultured  ||| S:774 E:783 ||| FW
bovine  ||| S:783 E:790 ||| FW
renal  ||| S:790 E:796 ||| FW
NBL-1  ||| S:796 E:802 ||| FW
cells ||| S:802 E:807 ||| NNS
.  ||| S:807 E:809 ||| .
In  ||| S:809 E:812 ||| IN
the  ||| S:812 E:816 ||| DT
collecting  ||| S:816 E:827 ||| JJ
duct ||| S:827 E:831 ||| NN
,  ||| S:831 E:833 ||| ,
CsA  ||| S:833 E:837 ||| NNP
may  ||| S:837 E:841 ||| MD
cause  ||| S:841 E:847 ||| VB
hypertension  ||| S:847 E:860 ||| VBN
by  ||| S:860 E:863 ||| IN
stimulating  ||| S:863 E:875 ||| VBG
the  ||| S:875 E:879 ||| DT
epithelial  ||| S:879 E:890 ||| JJ
Na+  ||| S:890 E:894 ||| CD
channel  ||| S:894 E:902 ||| NN
( ||| S:902 E:903 ||| -LRB-
ENaC ||| S:903 E:907 ||| NNP
)  ||| S:907 E:909 ||| -RRB-
through  ||| S:909 E:917 ||| IN
a  ||| S:917 E:919 ||| DT
pathway  ||| S:919 E:927 ||| NN
associated  ||| S:927 E:938 ||| VBN
with  ||| S:938 E:943 ||| IN
inhibition  ||| S:943 E:954 ||| NN
of  ||| S:954 E:957 ||| IN
ABCA1  ||| S:957 E:963 ||| NNP
and  ||| S:963 E:967 ||| CC
consequent  ||| S:967 E:978 ||| JJ
elevation  ||| S:978 E:988 ||| NN
of  ||| S:988 E:991 ||| IN
cholesterol  ||| S:991 E:1003 ||| NN
in  ||| S:1003 E:1006 ||| IN
the  ||| S:1006 E:1010 ||| DT
cells ||| S:1010 E:1015 ||| NNS
.  ||| S:1015 E:1017 ||| .
It  ||| S:1017 E:1020 ||| PRP
is  ||| S:1020 E:1023 ||| VBZ
still  ||| S:1023 E:1029 ||| RB
unclear  ||| S:1029 E:1037 ||| JJ
whether  ||| S:1037 E:1045 ||| IN
CsA  ||| S:1045 E:1049 ||| NNP
regulates  ||| S:1049 E:1059 ||| VBZ
the  ||| S:1059 E:1063 ||| DT
Na+-Cl-  ||| S:1063 E:1071 ||| JJ
cotransporter  ||| S:1071 E:1085 ||| NN
in  ||| S:1085 E:1088 ||| IN
the  ||| S:1088 E:1092 ||| DT
distal  ||| S:1092 E:1099 ||| JJ
tubule  ||| S:1099 E:1106 ||| NN
and  ||| S:1106 E:1110 ||| CC
ENaC  ||| S:1110 E:1115 ||| JJ
in  ||| S:1115 E:1118 ||| IN
the  ||| S:1118 E:1122 ||| DT
collecting  ||| S:1122 E:1133 ||| JJ
duct ||| S:1133 E:1137 ||| NN
.  ||| S:1137 E:1139 ||| .
Aside  ||| S:1139 E:1145 ||| RB
from  ||| S:1145 E:1150 ||| IN
this ||| S:1150 E:1154 ||| DT
,  ||| S:1154 E:1156 ||| ,
there  ||| S:1156 E:1162 ||| EX
is  ||| S:1162 E:1165 ||| VBZ
evidence  ||| S:1165 E:1174 ||| NN
suggesting  ||| S:1174 E:1185 ||| VBG
the  ||| S:1185 E:1189 ||| DT
possible  ||| S:1189 E:1198 ||| JJ
involvement  ||| S:1198 E:1210 ||| NN
of  ||| S:1210 E:1213 ||| IN
free  ||| S:1213 E:1218 ||| JJ
radicals  ||| S:1218 E:1227 ||| NNS
during  ||| S:1227 E:1234 ||| IN
the  ||| S:1234 E:1238 ||| DT
development  ||| S:1238 E:1250 ||| NN
of  ||| S:1250 E:1253 ||| IN
CsA-induced  ||| S:1253 E:1265 ||| JJ
hypertension ||| S:1265 E:1277 ||| NN
.  ||| S:1277 E:1279 ||| .
The  ||| S:1279 E:1283 ||| DT
hypertensive  ||| S:1283 E:1296 ||| JJ
effect  ||| S:1296 E:1303 ||| NN
is ||| S:1303 E:1305 ||| VBZ
,  ||| S:1305 E:1307 ||| ,
most  ||| S:1307 E:1312 ||| RBS
probably ||| S:1312 E:1320 ||| RB
,  ||| S:1320 E:1322 ||| ,
correlated  ||| S:1322 E:1333 ||| VBG
with  ||| S:1333 E:1338 ||| IN
higher  ||| S:1338 E:1345 ||| JJR
levels  ||| S:1345 E:1352 ||| NNS
of  ||| S:1352 E:1355 ||| IN
superoxide  ||| S:1355 E:1366 ||| NNS
( ||| S:1366 E:1367 ||| -LRB-
O2- ||| S:1367 E:1370 ||| NNP
)  ||| S:1370 E:1372 ||| -RRB-
that  ||| S:1372 E:1377 ||| WDT
decreases  ||| S:1377 E:1387 ||| VBZ
glomerular  ||| S:1387 E:1398 ||| JJ
filtration  ||| S:1398 E:1409 ||| JJ
rate  ||| S:1409 E:1414 ||| NN
and  ||| S:1414 E:1418 ||| CC
may  ||| S:1418 E:1422 ||| MD
affect  ||| S:1422 E:1429 ||| VB
fluid  ||| S:1429 E:1435 ||| JJ
reabsorption  ||| S:1435 E:1448 ||| NN
along  ||| S:1448 E:1454 ||| IN
the  ||| S:1454 E:1458 ||| DT
nephron ||| S:1458 E:1465 ||| NN
.  ||| S:1465 E:1467 ||| .
